메뉴 건너뛰기




Volumn 99, Issue 5, 2016, Pages 538-547

Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEGLITINIDE; METFORMIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT;

EID: 84955119852     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.297     Document Type: Article
Times cited : (22)

References (50)
  • 1
    • 78149373656 scopus 로고    scopus 로고
    • Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence
    • 29-7954-8-29
    • Boyle J.P., Thompson T.J., Gregg E.W., Barker L.E., & Williamson D.F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health. Metr. 8, 29-7954-8-29 (2010).
    • (2010) Popul. Health. Metr. , vol.8
    • Boyle, J.P.1    Thompson, T.J.2    Gregg, E.W.3    Barker, L.E.4    Williamson, D.F.5
  • 2
    • 1542618210 scopus 로고    scopus 로고
    • Hypoglycemia as a barrier to glycemic control
    • Davis S., & Alonso M.D. Hypoglycemia as a barrier to glycemic control. J. Diabetes Complications 18, 60-68 (2004).
    • (2004) J. Diabetes Complications , vol.18 , pp. 60-68
    • Davis, S.1    Alonso, M.D.2
  • 3
    • 84896039279 scopus 로고    scopus 로고
    • Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia
    • Anderson M., Powell J., Campbell K.M., & Taylor J.R. Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia. Diabetes Metab. Syndr. Obes. 7, 85-94 (2014).
    • (2014) Diabetes Metab. Syndr. Obes. , vol.7 , pp. 85-94
    • Anderson, M.1    Powell, J.2    Campbell, K.M.3    Taylor, J.R.4
  • 4
    • 0034912477 scopus 로고    scopus 로고
    • Hypoglycemia in patients with type 2 diabetes mellitus
    • Miller C.D., et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch. Intern. Med. 161, 1653-1659 (2001).
    • (2001) Arch. Intern. Med. , vol.161 , pp. 1653-1659
    • Miller, C.D.1
  • 5
    • 84879643475 scopus 로고    scopus 로고
    • Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus
    • Yaffe K., et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern. Med. 173, 1300-1306 (2013).
    • (2013) JAMA Intern. Med. , vol.173 , pp. 1300-1306
    • Yaffe, K.1
  • 6
    • 0036835434 scopus 로고    scopus 로고
    • Incidence and costs of severe hypoglycemia
    • Holstein A., Plaschke A., & Egberts E.H. Incidence and costs of severe hypoglycemia. Diabetes Care 25, 2109-2110 (2002).
    • (2002) Diabetes Care , vol.25 , pp. 2109-2110
    • Holstein, A.1    Plaschke, A.2    Egberts, E.H.3
  • 7
    • 84962964135 scopus 로고    scopus 로고
    • US Department of Health and Human Services Office of Disease Prevention and Health Promotion. 3 November Asp#action-plan. (2014). Accessed
    • US Department of Health and Human Services Office of Disease Prevention and Health Promotion. National action plan for adverse drug event prevention. http://www.health.gov/hcq/ade. asp#action-plan. 2014). Accessed 3 November 2015.
    • (2015) National Action Plan for Adverse Drug Event Prevention
  • 8
    • 84930465070 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2015: Summary of revisions
    • suppl.
    • Standards of medical care in diabetes-2015: summary of revisions Diabetes Care 38 (suppl.), S4-S003 (2015).
    • (2015) Diabetes Care , vol.38 , pp. S4-S13
  • 10
    • 0024515411 scopus 로고
    • Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents
    • Jennings A.M., Wilson R.M., & Ward J.D. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 12, 203-208 (1989).
    • (1989) Diabetes Care , vol.12 , pp. 203-208
    • Jennings, A.M.1    Wilson, R.M.2    Ward, J.D.3
  • 11
    • 0024586640 scopus 로고
    • Drug-induced hypoglycemia A review of 1418 cases
    • Seltzer H.S. Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol. Metab. Clin. North Am. 18, 163-183 (1989).
    • (1989) Endocrinol. Metab. Clin. North Am. , vol.18 , pp. 163-183
    • Seltzer, H.S.1
  • 13
    • 70349989948 scopus 로고    scopus 로고
    • Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide
    • Zharikova O.L., et al. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem. Pharmacol. 78, 1483-1490 (2009).
    • (2009) Biochem. Pharmacol. , vol.78 , pp. 1483-1490
    • Zharikova, O.L.1
  • 14
    • 76949099719 scopus 로고    scopus 로고
    • The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
    • Tan B., Zhang Y.F., Chen X.Y., Zhao X.H., Li G.X., & Zhong D.F. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur. J. Clin. Pharmacol. 66, 145-151 (2010).
    • (2010) Eur. J. Clin. Pharmacol. , vol.66 , pp. 145-151
    • Tan, B.1    Zhang, Y.F.2    Chen, X.Y.3    Zhao, X.H.4    Li, G.X.5    Zhong, D.F.6
  • 15
    • 0035208395 scopus 로고    scopus 로고
    • Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride
    • Niemi M., Neuvonen P.J., & Kivisto K.T. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin. Pharmacol. Ther. 70, 439-445 (2001).
    • (2001) Clin. Pharmacol. Ther. , vol.70 , pp. 439-445
    • Niemi, M.1    Neuvonen, P.J.2    Kivisto, K.T.3
  • 16
    • 36549038966 scopus 로고    scopus 로고
    • PPAR agonists: Multimodal drugs for the treatment of type-2 diabetes
    • Gross B., & Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 21, 687-710 (2007).
    • (2007) Best Pract. Res. Clin. Endocrinol. Metab. , vol.21 , pp. 687-710
    • Gross, B.1    Staels, B.2
  • 18
  • 19
    • 84856249507 scopus 로고    scopus 로고
    • Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide
    • Skoff R.A., Waterbury N.V., Shaw R.F., Egge J.A., & Cantrell M. Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide. J. Manag. Care. Pharm. 17, 664-671 (2011).
    • (2011) J. Manag. Care. Pharm. , vol.17 , pp. 664-671
    • Skoff, R.A.1    Waterbury, N.V.2    Shaw, R.F.3    Egge, J.A.4    Cantrell, M.5
  • 21
    • 0029042639 scopus 로고
    • Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulindependent diabetes mellitus
    • Appel S., et al. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulindependent diabetes mellitus. Am. J. Cardiol. 76, 29A-32A (1995).
    • (1995) Am. J. Cardiol. , vol.76 , pp. 29A-32A
    • Appel, S.1
  • 22
    • 84906519682 scopus 로고    scopus 로고
    • Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins
    • Schelleman H., et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br. J. Clin. Pharmacol. 78, 639-648 (2014).
    • (2014) Br. J. Clin. Pharmacol. , vol.78 , pp. 639-648
    • Schelleman, H.1
  • 23
    • 84911389837 scopus 로고    scopus 로고
    • Pharmacotherapy of type 2 diabetes mellitus: An update on drug-drug interactions
    • Amin M., & Suksomboon N. Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions. Drug Saf. 37, 903-919 (2014).
    • (2014) Drug Saf. , vol.37 , pp. 903-919
    • Amin, M.1    Suksomboon, N.2
  • 24
    • 0036725464 scopus 로고    scopus 로고
    • Interaction between free fatty acids and glucose metabolism
    • Boden G. Interaction between free fatty acids and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care 5, 545-549 (2002).
    • (2002) Curr. Opin. Clin. Nutr. Metab. Care , vol.5 , pp. 545-549
    • Boden, G.1
  • 25
    • 0036686288 scopus 로고    scopus 로고
    • Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle
    • Furuhashi M., et al. Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J. Endocrinol. 174, 321-329 (2002).
    • (2002) J. Endocrinol. , vol.174 , pp. 321-329
    • Furuhashi, M.1
  • 26
    • 0033964873 scopus 로고    scopus 로고
    • Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients
    • Mussoni L., et al. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis 148, 397-406 (2000).
    • (2000) Atherosclerosis , vol.148 , pp. 397-406
    • Mussoni, L.1
  • 27
    • 11844254843 scopus 로고    scopus 로고
    • Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia
    • Damci T., Tatliagac S., Osar Z., & Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur. J. Intern. Med. 14, 357-360 (2003).
    • (2003) Eur. J. Intern. Med. , vol.14 , pp. 357-360
    • Damci, T.1    Tatliagac, S.2    Osar, Z.3    Ilkova, H.4
  • 29
    • 2442660528 scopus 로고    scopus 로고
    • Peroxisome proliferator-Activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease
    • Tenenbaum A., et al. Peroxisome proliferator-Activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109, 2197-2202 (2004).
    • (2004) Circulation , vol.109 , pp. 2197-2202
    • Tenenbaum, A.1
  • 31
    • 84879490766 scopus 로고    scopus 로고
    • US Government Claims Databases
    • eds. Strom B.L., Kimmel S.E., & Hennessy S.) (Wiley-Blackwell, Hoboken, NJ
    • Hennessy S., Freeman C.P., & Cunningham F. US Government Claims Databases. In Pharmacoepidemiology eds. Strom B.L., Kimmel S.E., & Hennessy S.) 209 (Wiley-Blackwell, Hoboken, NJ, 2012).
    • Pharmacoepidemiology , vol.209 , pp. 2012
    • Hennessy, S.1    Freeman, C.P.2    Cunningham, F.3
  • 33
    • 36248988474 scopus 로고    scopus 로고
    • Quality of medicaid and medicare data obtained through centers for medicare and medicaid services cms)
    • Hennessy S., Leonard C.E., Palumbo C.M., Newcomb C., & Bilker W.B. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med. Care 45, 1216-1220 (2007).
    • (2007) Med. Care , vol.45 , pp. 1216-1220
    • Hennessy, S.1    Leonard, C.E.2    Palumbo, C.M.3    Newcomb, C.4    Bilker, W.B.5
  • 34
    • 0345356534 scopus 로고    scopus 로고
    • Cytochrome P450: Major player in reperfusion injury
    • Gottlieb R.A. Cytochrome P450: major player in reperfusion injury. Arch. Biochem. Biophys. 420, 262-267 (2003).
    • (2003) Arch. Biochem. Biophys. , vol.420 , pp. 262-267
    • Gottlieb, R.A.1
  • 37
    • 20444497396 scopus 로고    scopus 로고
    • Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients
    • Gannage-Yared M.H., et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 54, 947-951 (2005).
    • (2005) Metabolism , vol.54 , pp. 947-951
    • Gannage-Yared, M.H.1
  • 38
    • 47649118770 scopus 로고    scopus 로고
    • Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: Diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study
    • Tajima N., et al. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 199, 455-462 (2008).
    • (2008) Atherosclerosis , vol.199 , pp. 455-462
    • Tajima, N.1
  • 39
    • 34548500220 scopus 로고    scopus 로고
    • Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease
    • Sugiyama S., et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 194, e43-51 2007).
    • (2007) Atherosclerosis , vol.194 , pp. e43-e51
    • Sugiyama, S.1
  • 40
    • 0028039904 scopus 로고
    • Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia
    • Sheu W.H., et al. Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia. Am. Heart J. 127, 331-336 (1994).
    • (1994) Am. Heart J. , vol.127 , pp. 331-336
    • Sheu, W.H.1
  • 41
    • 67651042983 scopus 로고    scopus 로고
    • High-dimensional propensity score adjustment in studies of treatment effects using health care claims data
    • Schneeweiss S., Rassen J.A., Glynn R.J., Avorn J., Mogun H., & Brookhart M.A. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20, 512-522 (2009).
    • (2009) Epidemiology , vol.20 , pp. 512-522
    • Schneeweiss, S.1    Rassen, J.A.2    Glynn, R.J.3    Avorn, J.4    Mogun, H.5    Brookhart, M.A.6
  • 43
    • 42449099434 scopus 로고    scopus 로고
    • Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits
    • Ginde A.A., Blanc P.G., Lieberman R.M., & Camargo C.A., Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 8, 4 (2008).
    • (2008) BMC Endocr Disord. , vol.8 , pp. 4
    • Ginde, A.A.1    Blanc, P.G.2    Lieberman, R.M.3    Camargo, C.A.4
  • 44
  • 45
    • 79958845225 scopus 로고    scopus 로고
    • Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples
    • Rassen J.A., Glynn R.J., Brookhart M.A., & Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am. J. Epidemiol. 173, 1404-1413 (2011).
    • (2011) Am. J. Epidemiol. , vol.173 , pp. 1404-1413
    • Rassen, J.A.1    Glynn, R.J.2    Brookhart, M.A.3    Schneeweiss, S.4
  • 47
    • 77951622706 scopus 로고
    • The central role of the propensity score in observational studies for causal effects
    • Rosenbaum P.R., & Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 41-55 1983).
    • (1983) Biometrika , pp. 41-55
    • Rosenbaum, P.R.1    Rubin, D.B.2
  • 48
    • 84861097401 scopus 로고    scopus 로고
    • Propensity score applied to survival data analysis through proportional hazards models: A Monte Carlo study
    • Gayat E., Resche-Rigon M., Mary J.Y., & Porcher R. Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharm. Stat. 11, 222-229 (2012).
    • (2012) Pharm. Stat. , vol.11 , pp. 222-229
    • Gayat, E.1    Resche-Rigon, M.2    Mary, J.Y.3    Porcher, R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.